<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02769130</url>
  </required_header>
  <id_info>
    <org_study_id>1000051475</org_study_id>
    <nct_id>NCT02769130</nct_id>
  </id_info>
  <brief_title>Pilot Trial: the Safety and Feasibility of Losartan for Pulmonary Vein Stenosis</brief_title>
  <official_title>Pilot Trial: the Safety and Feasibility of Losartan Therapy for Treatment of Pulmonary Vein Stenosis in Pediatric Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Hospital for Sick Children</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Hospital for Sick Children</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot study evaluates the safety and feasibility of losartan in pediatric patients with
      pulmonary vein stenosis.

      It is an open label single arm interventional study. The patient population involves
      pediatric patients with stenosis in 2 or more pulmonary veins. Patients will be given
      losartan for 1 year. Outcomes include measures of safety/adverse events and progression of
      pulmonary vein stenosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This pilot study evaluates the safety and feasibility of losartan in pediatric patients with
      pulmonary vein stenosis.

      Large animal studies have demonstrated that losartan can ameliorate the progression of
      pulmonary vein stenosis in a surgical model of pulmonary vein stenosis.

      There is no safety data for losartan in children &lt; 6months of age or in children with
      pulmonary vein stenosis. Therefore, this study will test the safety and feasibility of
      losartan in children in an open label single arm interventional study.

      Patient inclusion criteria includes stenosis involving 2 or more pulmonary veins. Patients
      who are consented into the trial with be on losartan therapy for one year. They will undergo
      study visits every 3 months. Patients will be screened for adverse events through biochemical
      tests, routine clinical tests and questionnaires.

      An exploratory efficacy analysis will compare progression of pulmonary vein stenosis in
      children enrolled in losartan to a contemporary cohort of children with pulmonary vein
      stenosis, who did not receive losartan.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety:Number of participants with adverse events</measure>
    <time_frame>12 months</time_frame>
    <description>adverse events include hypotension, hyperkalemia, renal dysfunction</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Feasibility:Number of participants eligible and recruited</measure>
    <time_frame>12 months</time_frame>
    <description>includes patient recruitment and compliance with protocol</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression of pulmonary vein stenosis: survival</measure>
    <time_frame>12 months</time_frame>
    <description>Progression of pulmonary vein stenosis measures include survival, morbidity and evidence of progression on clinical tests</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Pulmonary Vein Stenosis</condition>
  <condition>Children</condition>
  <arm_group>
    <arm_group_label>Losartan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Losartan will be given to children with stenosis in greater or equal to 2 pulmonary veins.
Maintenance daily dosing is 1mg/kg/day using suspension or tablet formulation of losartan. Losartan will be given for 1 year.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Losartan</intervention_name>
    <description>Losartan is given for 12 months</description>
    <arm_group_label>Losartan</arm_group_label>
    <other_name>Cozaar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Stenosis involving 2 or more pulmonary veins

          -  Consent of parent/legal guardian or child(when appropriate)

        Exclusion Criteria:

          -  History of angioedema or allergic reaction to angiotensin converting enzyme inhibitors

          -  corrected gestational age of less than 40 weeks

          -  severe renal dysfunction

          -  pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher A Caldarone, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Hospital for Sick Children</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rachel D Vanderlaan, MD,PhD</last_name>
    <phone>416-262-8810</phone>
    <email>rachel.vanderlaan@sickkids.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christopher A Caldarone, MD</last_name>
    <phone>416-813-6420</phone>
    <email>christopher.caldarone@sickkids.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>m5g 0a4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Vanderlaan, MD,Phd</last_name>
      <phone>416-262-8810</phone>
      <email>rachel.vanderlaan@sickkids.ca</email>
    </contact>
    <investigator>
      <last_name>Rachel D Vanderlaan, MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christopher A Caldarone, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lars Grosse Wortmann, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jennifer Russell, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 9, 2016</study_first_submitted>
  <study_first_submitted_qc>May 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 11, 2016</study_first_posted>
  <last_update_submitted>May 9, 2016</last_update_submitted>
  <last_update_submitted_qc>May 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Hospital for Sick Children</investigator_affiliation>
    <investigator_full_name>Christopher Caldarone</investigator_full_name>
    <investigator_title>Surgeon in Chief</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constriction, Pathologic</mesh_term>
    <mesh_term>Stenosis, Pulmonary Vein</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Losartan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

